30M Genomics Profile
Key Indicators
- Authorised Capital ₹ 1.60 M
as on 03-12-2024
- Paid Up Capital ₹ 0.12 M
as on 03-12-2024
- Company Age 5 Year, 5 Months
- Last Filing with ROC 31 Mar 2024
- Revenue 584.40%
(FY 2022)
- Profit -45.96%
(FY 2022)
- Ebitda -316.13%
(FY 2022)
- Net Worth 2173.52%
(FY 2022)
- Total Assets 202.43%
(FY 2022)
About 30M Genomics
The Company is engaged in the Non-Profit Organizations Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 1.60 M and a paid-up capital of Rs 0.12 M, as per Ministry of Corporate Affairs (MCA) records.
Benet Dhas and Sasikanta Pavuluri serve as directors at the Company.
- CIN/LLPIN
U85300AP2019PTC112451
- Company No.
112451
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
18 Jul 2019
- Date of AGM
30 Sep 2024
- Date of Balance Sheet
31 Mar 2024
- Listing Status
Unlisted
- ROC Code
Roc Vijayawada
Industry
Company Details
- Location
Godavari, Andhra Pradesh, India
- Telephone
- Email Address
- Website
- Social Media-
Who are the key members and board of directors at 30M Genomics?
Board Members(2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Benet Dhas  | Director | 18-Jul-2019 | Current |
| Sasikanta Pavuluri | Director | 18-Jul-2019 | Current |
Financial Performance of 30M Genomics.
30M Genomics Private Limited, for the financial year ended 2022, experienced significant growth in revenue, with a 584.4% increase. The company also saw a substantial fall in profitability, with a 45.96% decrease in profit. The company's net worth Soared by an impressive increase of 2173.52%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations | |||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of 30M Genomics?
In 2022, 30M Genomics had a public holding of 4.76%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Charges (Loans)
There are no open charges registered against the company as per our records.
How Many Employees Work at 30M Genomics?
Unlock and access historical data on people associated with 30M Genomics, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of 30M Genomics, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped 30M Genomics's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
